Boric Acid and Commercial Organoboron Products as Inhibitors of Drug-Resistant Candida albicans

Bryan Larsen, Marija Petrovic, Francesco DeSeta

Research output: Contribution to journalArticle

Abstract

© 2017 Springer Science+Business Media B.V. Clinical use of boric acid as a topical antifungal in women who have failed standard antifungal therapy with azole drugs has been used sporadically for decades. Our previous in vitro work showing inhibition of Candida albicans growth was conducted on clinical isolates without antifungal drug susceptibility profiling. Here, we report that boric acid restricts growth of drug-resistant Candida albicans and inhibits hyphal growth and diminishes cell volume. The availability of over-the-counter organoboron compounds intended for use as oral nutritional supplements led us to determine if these also were inhibitory toward resistant Candida and show here that they also possess antifungal activity. Candida glabrata was also found to be inhibited by boric acid and organoboron compounds. Further development of organoboron compounds as topical therapeutics is of potential value.
Original languageEnglish
Pages (from-to)1-9
Number of pages9
JournalMycopathologia
DOIs
Publication statusAccepted/In press - Oct 9 2017

Fingerprint

boric acid
Candida albicans
drugs
Growth
Pharmaceutical Preparations
Candida glabrata
azoles
Azoles
therapeutics
antifungal agents
Candida
Cell Size
dietary supplements
mouth
Therapeutics
cells

Keywords

  • Boric acid
  • Candida albicans
  • Candida glabrata
  • Drug resistant
  • Organoboron

Cite this

Boric Acid and Commercial Organoboron Products as Inhibitors of Drug-Resistant Candida albicans. / Larsen, Bryan; Petrovic, Marija; DeSeta, Francesco.

In: Mycopathologia, 09.10.2017, p. 1-9.

Research output: Contribution to journalArticle

@article{e0a97a362f1b460ea51dd4ae2d8c139b,
title = "Boric Acid and Commercial Organoboron Products as Inhibitors of Drug-Resistant Candida albicans",
abstract = "{\circledC} 2017 Springer Science+Business Media B.V. Clinical use of boric acid as a topical antifungal in women who have failed standard antifungal therapy with azole drugs has been used sporadically for decades. Our previous in vitro work showing inhibition of Candida albicans growth was conducted on clinical isolates without antifungal drug susceptibility profiling. Here, we report that boric acid restricts growth of drug-resistant Candida albicans and inhibits hyphal growth and diminishes cell volume. The availability of over-the-counter organoboron compounds intended for use as oral nutritional supplements led us to determine if these also were inhibitory toward resistant Candida and show here that they also possess antifungal activity. Candida glabrata was also found to be inhibited by boric acid and organoboron compounds. Further development of organoboron compounds as topical therapeutics is of potential value.",
keywords = "Boric acid, Candida albicans, Candida glabrata, Drug resistant, Organoboron",
author = "Bryan Larsen and Marija Petrovic and Francesco DeSeta",
year = "2017",
month = "10",
day = "9",
doi = "10.1007/s11046-017-0209-6",
language = "English",
pages = "1--9",
journal = "Mycopathologia",
issn = "0301-486X",
publisher = "Springer Netherlands",

}

TY - JOUR

T1 - Boric Acid and Commercial Organoboron Products as Inhibitors of Drug-Resistant Candida albicans

AU - Larsen, Bryan

AU - Petrovic, Marija

AU - DeSeta, Francesco

PY - 2017/10/9

Y1 - 2017/10/9

N2 - © 2017 Springer Science+Business Media B.V. Clinical use of boric acid as a topical antifungal in women who have failed standard antifungal therapy with azole drugs has been used sporadically for decades. Our previous in vitro work showing inhibition of Candida albicans growth was conducted on clinical isolates without antifungal drug susceptibility profiling. Here, we report that boric acid restricts growth of drug-resistant Candida albicans and inhibits hyphal growth and diminishes cell volume. The availability of over-the-counter organoboron compounds intended for use as oral nutritional supplements led us to determine if these also were inhibitory toward resistant Candida and show here that they also possess antifungal activity. Candida glabrata was also found to be inhibited by boric acid and organoboron compounds. Further development of organoboron compounds as topical therapeutics is of potential value.

AB - © 2017 Springer Science+Business Media B.V. Clinical use of boric acid as a topical antifungal in women who have failed standard antifungal therapy with azole drugs has been used sporadically for decades. Our previous in vitro work showing inhibition of Candida albicans growth was conducted on clinical isolates without antifungal drug susceptibility profiling. Here, we report that boric acid restricts growth of drug-resistant Candida albicans and inhibits hyphal growth and diminishes cell volume. The availability of over-the-counter organoboron compounds intended for use as oral nutritional supplements led us to determine if these also were inhibitory toward resistant Candida and show here that they also possess antifungal activity. Candida glabrata was also found to be inhibited by boric acid and organoboron compounds. Further development of organoboron compounds as topical therapeutics is of potential value.

KW - Boric acid

KW - Candida albicans

KW - Candida glabrata

KW - Drug resistant

KW - Organoboron

UR - http://www.scopus.com/inward/record.url?scp=85030853205&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030853205&partnerID=8YFLogxK

U2 - 10.1007/s11046-017-0209-6

DO - 10.1007/s11046-017-0209-6

M3 - Article

AN - SCOPUS:85030853205

SP - 1

EP - 9

JO - Mycopathologia

JF - Mycopathologia

SN - 0301-486X

ER -